Jci_page_head_homepage_01 Jci_page_head_homepage_02
Paul Varghese, Robert W. Harrison, Robert A. Lofthouse, Dimitrios Georgakopoulos, Dan E. Berkowitz, Joshua M. Hare
Published in Volume 106, Issue 5
J Clin Invest. 2000; 106(5):697–703 doi:10.1172/JCI9323
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 2

(a) Contractile effects of isoproterenol and L-NMMA in WT, β3–/–, and NOS3–/– mice. Isoproterenol was administered intravenously at a rate of 5 ng/kg/min for 4 minutes, followed by a co-infusion with L-NMMA at 10 mg/kg/h for 5 minutes. Contractility was indexed by dP/dt-IP and is shown as a percentage of change from base line. The β3–/– mice (n = 10) had greater responses to isoproterenol than did the WT mice (n = 8), but did not show any further augmentation after NOS inhibition with L-NMMA. Similarly, NOS3–/– mice (n = 15) were hyper-responsive to isoproterenol. L-NMMA augmented the isoproterenol response in WT mice to the level observed in β3–/– mice. (b) The effect of an additional NOS inhibitor, L-NAME. L-NAME had an effect similar to L-NMMA, augmenting the response to isoproterenol in WT, but not β3–/–, mice. Data are reported as mean ± SEM. AP < 0.05 vs. respective base line; BP < 0.01 vs. respective base line; CP < 0.05 vs. WT isoproterenol response by one-way ANOVA.